RemAb Therapeutics
Removing harmful antibodies.
Removing harmful antibodies.
RemAb Therapeutics is a biopharmaceutical company founded in 2018 with a focus on removing harmful antibodies. The company's expertise lies in the identification, characterization, and selective removal of specific antibodies using their proprietary HART-Technology. With a strong presence in Spain, RemAb Therapeutics operates in the biotechnology and healthcare industries, offering solutions in infectious diseases, allergology, autoimmunity, transplantation and transfusion medicine, as well as the modulation of human immune responses against viral vectors.
Having secured a $71.43K grant investment on 01 January 2019, RemAb Therapeutics has garnered support from notable investors such as EASME - EU Executive Agency for SMEs. The company's innovative approach to targeting specific antibodies and its diverse applications in healthcare make it a promising venture for potential investors in the biopharmaceutical sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $71.43K | 1 | EASME - EU Executive Agency for SMEs | 01 Jan 2019 |
| Grant | Unknown | 1 | EIT Health | 19 Sep 2018 |
No recent news or press coverage available for RemAb Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
